Paolo Tarantino
@PTarantinoMD
MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.
In 2020 we proposed to add a #HER2Low slice to the HER2 pie chart, an addition that has now entered practice. But further changes await us in the coming years. Excited to share our latest Cancer Discovery piece, outlining the present & future of HER2-low! aacrjournals.org/cancerdiscover…
Love seeing #Advocate extraordinaire @itsnot_pink representing the patient voice!
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
Gene expression profiling in breast cancer brain mets Among matched pairs, 42% lost ER, 55% lost PR, 45% gained HER2 & 42% acquired a basal-like phenotype. BM showed ↓luminal markers & ↑immune genes, revealing molecular divergence from the primaries esmoopen.com/article/S2059-…
.@FilipaLynce, MD, FASCO, recently received the Advanced Clinical Research Award in Breast Cancer Research from @ConquerCancerFd. Lynce's work will focus on deciphering mechanisms of response to novel therapies in HER2 expressing stage III Inflammatory Breast Cancer, paving the…
Results from the VIKTORIA-1 phase 3 trial (2L fulv/palbo/geda vs fulv/geda vs fulv) to be disclosed next Monday morningstar.com/news/globe-new…
🎥 Orgogliosi del nostro Paolo Tarantino! Un esempio concreto del talento che può emergere dalla Scuola di Specializzazione in Oncologia Medica @LaStatale @IEOufficiale @PTarantinoMD Impegno clinico, ricerca internazionale e formazione di eccellenza.
Se sei un medico in procinto di scegliere la scuola di specializzazione in oncologia, ho un consiglio per te: scegli Milano, scegli UniMi!
📣 Titles of poster and oral presentations for the European Society for Medical Oncology (@myESMO) Congress 2025 have been released. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #ESMO25 #CancerResearch…
Se sei un medico in procinto di scegliere la scuola di specializzazione in oncologia, ho un consiglio per te: scegli Milano, scegli UniMi!
The use of machine learning models to predict PFS and OS outcomes from waterfall plots in RCTs (MAP-OUTCOMES) in @ESMO_Open. ML tool using depth of response with non-cytotoxic therapies predicting survival, potentially supporting go-no-go decisions. esmoopen.com/article/S2059-…
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis in @ESMO_Open. 229 pts, 169 treated with 1st line Tx, 68.6% PD-L1 high, 39.7% KRAS mut. Longer PFS and OS with ICIs+/-CT as compared to CT alone. esmoopen.com/article/S2059-…
Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. esmoopen.com/article/S2059-…
🗨️ “It’s the best single agent treatment that we ever developed for metastatic #breastcancer.” @PTarantinoMD of @DanaFarber @Harvard on the real-world efficacy of trastuzumab deruxtecan, published in @ESMO_Open. @AstraZeneca @DaiichiSankyoUS bit.ly/4f2XQL3
Thanks @DrKatyMoore @PTarantinoMD for organizing such a state of the art session on everything about ADCs across solid tumors and the invite to talk about ADCs in GU cancers! What an incredible session with an all ⭐️ faculty with the best part being the realistic and poignant…
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
I felt surrounded by brilliant, innovative, patient centered colleagues today. Thank you all for coming to DC
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
Thanks @DrKatyMoore @PTarantinoMD for putting this fantastic program together and inviting me! Some excellent talks from other experts @BiagioRicciutMD and others! @NRGonc
Outstanding presentation at @NRGonc summer symposium on ADCs by @StephensonCC’s own @thenasheffect
Terrific closing for the @NRGonc ADC symposium, with Lauren Price from the @US_FDA highlighting the evolution of dose-optimization strategies for ADCs. Lots of work ongoing to identify the RIGHT dose of ADC treatments as EARLY as possible during development.
Tangible goal to implement for everyone including cancer patients. 5000 steps a day looks quite good for all cause mortality.
Some plateauing for associated risk reduction (odds ratio) many outcomes seen at 7,000 steps
Great overview of synergistic ADC combinations by Leif Ellisen (@MGHBreastOnc). Promising preclinical (and early clinical) results with the combination of ADCs and PARPi, and intriguing signals with proteasome inhibitors. @NRGonc
